JP2014513952A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513952A5
JP2014513952A5 JP2014506579A JP2014506579A JP2014513952A5 JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5 JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acids
kda
seq
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014506579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513952A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/034479 external-priority patent/WO2012145644A1/en
Publication of JP2014513952A publication Critical patent/JP2014513952A/ja
Publication of JP2014513952A5 publication Critical patent/JP2014513952A5/ja
Pending legal-status Critical Current

Links

JP2014506579A 2011-04-22 2012-04-20 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ Pending JP2014513952A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
US61/478,336 2011-04-22
PCT/US2012/034479 WO2012145644A1 (en) 2011-04-22 2012-04-20 Modified acid alpha glucosidase with accelerated processing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016185075A Division JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Publications (2)

Publication Number Publication Date
JP2014513952A JP2014513952A (ja) 2014-06-19
JP2014513952A5 true JP2014513952A5 (enExample) 2015-05-28

Family

ID=46000406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014506579A Pending JP2014513952A (ja) 2011-04-22 2012-04-20 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ
JP2016185075A Pending JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016185075A Pending JP2017035091A (ja) 2011-04-22 2016-09-23 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ

Country Status (24)

Country Link
US (1) US20140186326A1 (enExample)
EP (1) EP2699676A1 (enExample)
JP (2) JP2014513952A (enExample)
KR (1) KR20140037082A (enExample)
CN (1) CN103797115A (enExample)
AU (1) AU2012245280A1 (enExample)
BR (1) BR112013026976A2 (enExample)
CA (1) CA2833371A1 (enExample)
CL (1) CL2013003010A1 (enExample)
CO (1) CO6811810A2 (enExample)
CR (1) CR20130555A (enExample)
EC (1) ECSP13013036A (enExample)
GT (1) GT201300252A (enExample)
IL (1) IL228871A0 (enExample)
MA (1) MA35125B1 (enExample)
MX (1) MX2013012345A (enExample)
NI (1) NI201300110A (enExample)
PE (1) PE20140617A1 (enExample)
PH (1) PH12013502149A1 (enExample)
RU (1) RU2013151875A (enExample)
SG (2) SG194486A1 (enExample)
TN (1) TN2013000427A1 (enExample)
WO (1) WO2012145644A1 (enExample)
ZA (1) ZA201307696B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
HUE064629T2 (hu) 2014-09-30 2024-04-28 Amicus Therapeutics Inc Nagy potenciálú savas alfa-glükozidáz fokozott szénhidrátokkal
WO2017079729A1 (en) * 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
SG11201804965SA (en) 2015-12-30 2018-07-30 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
KR102343162B1 (ko) 2016-03-30 2021-12-23 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
KR20250017756A (ko) 2016-03-30 2025-02-04 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
AU2017322376B2 (en) 2016-09-12 2023-08-17 Association Institut De Myologie Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
SI3624831T1 (sl) 2017-05-15 2023-08-31 Amicus Therapeutics, Inc. Rekombinantna humana kisla alfa-glukozidaza
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
EP3749373A1 (en) 2018-02-07 2020-12-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
JP7477462B2 (ja) 2018-05-17 2024-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗cd63抗体、コンジュゲート、及び、それらの使用
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
IL293068A (en) * 2019-11-19 2022-07-01 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
JP4990434B2 (ja) * 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
ES2395463T3 (es) 2001-07-16 2013-02-15 Genzyme Corporation Un inhibidor de N-acilesfingosina glucosiltransferasa
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
CN1813066B (zh) 2003-06-24 2010-04-28 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2014513952A5 (enExample)
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
JP2014530253A5 (enExample)
JP2012095641A5 (enExample)
GB201018518D0 (en) Novel endolysin
JP2012041342A5 (enExample)
NZ701881A (en) Vaccines for hsv-2
NZ595063A (en) Polypeptides from neisseria meningitidis
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
JP2008530245A5 (enExample)
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
MX336412B (es) Nuevos analogos de glucagon.
JP2017529326A5 (enExample)
JPWO2019156137A5 (enExample)
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
JP2019533722A5 (enExample)
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
MX364623B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
EA201170917A1 (ru) Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
MY190257A (en) Optimised subcutaneous therapeutic agents
JP2014529399A5 (enExample)
JP2015514115A5 (enExample)
JP2018533970A5 (enExample)
JP2012521366A5 (enExample)